ClinicalTrials.gg
RecruitingNCT07948694ANGEL-IMPROVEUpdated Nov 19, 2026

Improving Endovascular Treatment Through Process Refinements

An interventional study of Multicomponent Quality Improvement Intervention in Acute Ischemic Stroke, sponsored by Beijing Tiantan Hospital. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Apr 2026, registered Nov 2026).
  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,862
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 86 studies in Ischemic Stroke by Beijing Tiantan Hospital — 46 open to participants now, 47 under way, 15 of them phase 3. Ischemic Stroke · Beijing Tiantan Hospital.

Planned enrollment
13th of 77
2,862 · median 564
Started
2026
with 18 others
No phase
31 of 86
15 open now
Primary completion
2026-11
later than 18 of 46 live
Registered
86th of 86
by date

Among the 86 studies in Ischemic Stroke by Beijing Tiantan Hospital, this one is the 13th largest by planned enrollment of the 77 interventional ones that give a count, is one of 19 that started in 2026, is one of 31 with no phase, reaches primary completion later than 18 of the 46 other live ones, and was the 86th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

46 of the 86 studies in Ischemic Stroke by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

40 more — sign in →

By country, each count listing its studies:

All 46 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 402 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Ischemic Stroke by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

This study aims to evaluate the effectiveness of a structured, multi-component intervention package-the TIPS system-in improving the workflow and outcomes of endovascular treatment (EVT) for acute ischemic stroke caused by large vessel occlusion (LVO) in China. Despite EVT being a guideline-recommended therapy, delays in workflow processes such as door-to-puncture time (DTP) and puncture-to-reperfusion time (PRT) remain widespread, especially in developing countries. The TIPS intervention focuses on key structure-process-outcome (SPO) elements and includes training \& discussion, indicator feedback, professional guidance, and a solutions toolkit, implemented through a PDSA (Plan-Do-Study-Act) cycle. This multicenter, cluster-randomized study will assess whether the TIPS intervention improves EVT process efficiency and patient functional outcomes (90-day mRS). The findings are expected to support quality improvement and promote equitable stroke care delivery across China.

Read the detailed description

This study aims to evaluate the effectiveness of a structured, multi-component quality improvement intervention (the TIPS system) in enhancing the workflow and patient outcomes of endovascular treatment (EVT) for acute ischemic stroke due to large vessel occlusion (LVO) in China. Although EVT is the guideline-recommended treatment, real-world data from both developed and developing countries demonstrate persistent delays in key workflow intervals, such as door-to-puncture time (DTP) and puncture-to-reperfusion time (PRT), which are associated with functional outcomes.

The TIPS system integrates four core components: Training \& Discussion, Indicator Feedback, Professional Guidance, and a Solutions Toolkit. It follows the Plan-Do-Study-Act (PDSA) model for continuous quality improvement and is built on the structure-process-outcome (SPO) framework. The intervention involves structured training, real-time data monitoring using an electronic data capture (EDC) platform, a 24/7 expert consultation team, and smart workflow tools such as the iStroke system and GreenFast app to support process tracking and decision-making.

ANGEL-IMPROVE is a multicenter, prospective, open-label, cluster-randomized trial with blinded endpoint assessment. A total of 100 tertiary hospitals across China will be stratified and randomized to either the intervention or control group. The study will enroll approximately 1,400 adult patients (≥18 years) receiving EVT. Control group hospitals will continue standard care; intervention group hospitals will implement the TIPS program.

The primary outcome is door-to-puncture time (DTP), defined as the time from arrival at the emergency department to arterial puncture, with a target of less than 90 minutes. Secondary outcomes include puncture-to-reperfusion time (PRT, target \<60 minutes), successful reperfusion defined as mTICI ≥2b, functional outcomes including the proportion of patients with modified Rankin Scale (mRS) 0-2 at 90 days, full mRS distribution, NIHSS scores at 24 hours and 7 days or discharge, and EQ-5D scores at 90 days. Safety outcomes include serious intraoperative complications (such as vessel perforation, dissection, or embolism), symptomatic intracranial hemorrhage within 48 hours based on Heidelberg criteria, any intracranial hemorrhage within 48 hours, stroke-related mortality, all-cause mortality, and serious adverse events within 90 days according to ICH-GCP definitions.

Statistical analysis will follow the intention-to-treat principle using the Full Analysis Set (FAS); Per Protocol Set (PPS) will be used for sensitivity analysis, and Safety Analysis Set (SAS) for safety evaluation. Continuous variables will be summarized as mean ± SD or median (IQR), and categorical variables as counts and percentages; group comparisons will use standard parametric or nonparametric tests. The primary outcome will be analyzed using generalized linear mixed models (GLMM) accounting for hospital-level clustering, time effects, and patient-level covariates. Secondary outcomes will be analyzed using ordinal logistic regression or Wilcoxon test for ordered variables, linear mixed models for continuous variables, and GLMM for binary outcomes; time-to-event outcomes will use Kaplan-Meier and Cox models. Safety events will be descriptively summarized in the SAS, with group comparisons using chi-square or Fisher's exact tests. All tests will be two-sided with a significance level of P \< 0.05.

This trial aims to develop a replicable, scalable model of EVT workflow optimization in low- and middle-income settings and promote more equitable access to high-quality stroke care in China.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligibility Criteria Inclusion Criteria for Participating Centers

  • Tertiary hospitals (county-level hospitals preferred)
  • Equipped with an emergency department and a neurology ward that admits stroke patients
  • Capable of performing intravenous thrombolysis and endovascular treatment for acute ischemic stroke
  • Availability of a 24/7 in-hospital stroke emergency response team
  • Site principal investigator (PI) is committed to promoting the study, and the stroke team is willing to follow the study protocol, including randomization and interventions

Inclusion Criteria for Patients

  • Age ≥ 18 years
  • Undergoing endovascular treatment for acute ischemic stroke
  • Admitted through the emergency department
  • Written obtained from the patient or legally authorized representative for participation and follow-up

Exclusion Criteria for Participating Centers

  • Specialty hospitals (e.g., oncology, obstetrics/gynecology, pediatrics)
  • Fewer than 50 EVT cases per year for acute ischemic stroke
  • Inability to comply with the study protocol
  • Participation in other stroke-related quality improvement programs or clinical trials

Exclusion Criteria for Patients

  • less than 3 months or presence of severe comorbidities
  • Refusal to provide informed consent or inability to complete follow-up due to lack of consent or data sharing restrictions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,862 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Participants in the intervention arm will receive the TIPS system, a structured quality improvement package designed to optimize EVT workflow. TIPS stands for Training \& discussion, Indicator feedback, Professional guidance, and Solutions toolkit. The intervention includes team-based training, data-driven performance feedback, expert-led consultations, and workflow tools such as iStroke and GreenFast, implemented through iterative Plan-Do-Study-Act (PDSA) cycles. Real-time monitoring and data management are supported by an integrated electronic data capture (EDC) platform.

    Procedure: Multicomponent Quality Improvement Intervention

  • No intervention
    Control Group

    Conventional Endovascular Treatment Process

Interventions

  • ProcedureMulticomponent Quality Improvement Intervention

    This intervention consists of a structured, multicomponent quality improvement program named TIPS, designed to optimize endovascular treatment (EVT) workflow in acute ischemic stroke. TIPS stands for Training \& Discussion, Indicator Feedback, Professional Guidance, and Solutions Toolkit. The program includes standardized training sessions, real-time performance feedback via an electronic data capture (EDC) system, 24/7 expert consultation, and process management tools such as the iStroke platform and GreenFast pathway. The intervention is delivered at the hospital level and implemented using a Plan-Do-Study-Act (PDSA) cycle. It is distinct from other QI initiatives by its structured SPO-based design (Structure-Process-Outcome) and its integration of real-time data monitoring and expert-guided iterative feedback.

06

What researchers measure

Primary outcomes

  1. Door-to-Puncture Time (DTP)

    DTP is defined as the time interval (in minutes) between a patient's arrival at the hospital emergency department (i.e., crossing the emergency entrance threshold) and the initiation of arterial access (puncture) in the angiography suite. It serves as a key indicator of workflow efficiency in endovascular treatment (EVT) for acute ischemic stroke. Shorter DTP is strongly associated with improved clinical outcomes. The threshold for achieving process quality is set at \<90 minutes, as recommended by international guidelines. Time is measured from hospital records and procedural logs.

    Time frame: Periprocedural (from hospital arrival to arterial puncture)

Secondary outcomes

  1. Puncture-to-Reperfusion Time (PRT)

    PRT is defined as the time interval between the start of arterial puncture and the achievement of successful reperfusion, as determined by digital subtraction angiography (DSA). It reflects intra-procedural efficiency during endovascular treatment (EVT). A PRT \<60 minutes is considered a quality benchmark. Time is recorded from procedure start to documented final angiographic run.

    Time frame: Periprocedural

  2. Successful Reperfusion (mTICI ≥2b)

    Successful reperfusion is defined as achieving a modified Thrombolysis in Cerebral Infarction (mTICI) score of 2b or higher on the final digital subtraction angiogram after EVT. This indicates restoration of adequate blood flow to the downstream territory. The mTICI scale ranges from 0 (no perfusion) to 3 (full perfusion), with 2b representing ≥50% filling of the affected territory.

    Time frame: Periprocedural

  3. Functional Independence (mRS 0-2 at 90 days)

    Functional independence is defined as a score of 0-2 on the modified Rankin Scale (mRS) at 90 days post-treatment. The mRS measures the degree of disability or dependence in daily activities, ranging from 0 (no symptoms) to 6 (death). A score of 0-2 indicates independence in most daily functions.

    Time frame: 90 days

  4. NIHSS Score at 24 Hours and 7 Days (or Discharge)

    The National Institutes of Health Stroke Scale (NIHSS) is a standardized measure used to assess neurological impairment following stroke. It ranges from 0 (no deficit) to 42 (severe stroke). NIHSS will be recorded at 24 hours and again at 7 days or hospital discharge, whichever occurs first, to monitor early neurological recovery.

    Time frame: 24 hours and 7 days (or Discharge)

  5. EQ-5D Quality of Life Score at 90 Days

    EQ-5D is a standardized measure of health-related quality of life consisting of five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each domain has five levels of severity. Patients (or caregivers) will complete the EQ-5D questionnaire via structured follow-up interview at 90 days to assess overall health status.

    Time frame: 90 days

  6. All-cause mortality rate

    All-cause mortality rate at 90±14 days

    Time frame: 90 days

  7. Any type of intracranial hemorrhage

    Any type of intracranial hemorrhage according to Heidelberg Classification.

    Time frame: 36 hours

  8. Symptomatic Intracranial Hemorrhage

    Symptomatic Intracranial Hemorrhage according to Heidelberg Classification.

    Time frame: 36 hours

  9. Serious Intraoperative Complications

    Defined as major adverse events occurring during the endovascular procedure, including but not limited to vessel perforation, dissection, acute occlusion, device malfunction (e.g., breakage), or distal embolization. These events require clinical intervention, may lead to procedure termination, and are considered to have potential impact on patient prognosis.

    Time frame: Periprocedural

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2026, 7 months after the start.

Of 574 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 7 months is below that.

Counting every sponsor, half of 655 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 19, 2026
StartActual
Apr 15, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Feb 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948694
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Apr 15, 2026
Primary completion
Nov 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Dapeng Sun
Contact
sundp1990@163.com
86-19520064886

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion